Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
+$0.15 today
- Market cap
- $1.54B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
Volume 2.79M
Average 1.74M
NRIX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Nurix Therapeutics, Inc.NASDAQ: NRIX
Net Income · Q3 FY2026 · quarter ended Aug 2026
Net income turns positive
Q3 FY2026 net income was $549.81M, compared with -$86.42M a year earlier. Trailing-twelve-month net income was $294.88M. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Net income amounted to 314.9% of revenue in FY2025, down 39.9 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of $344M (+230.1%) for the fiscal year ending Nov 2026, a step up from the +36.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterAug 2026
- $549.81M+714.1% QoQ
- Last fiscal yearNov 2025
- -$264.46M+36.6% YoY
- LTMAug 2026
- $294.88M+220.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (264.46M) USD
- Year-over-year change
- -36.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-11-30 | (264.46M) | -36.6% |
| FY2024 | 2024-11-30 | (193.57M) | -34.5% |
| FY2023 | 2023-11-30 | (143.95M) | +20.2% |
| FY2022 | 2022-11-30 | (180.36M) | -53.9% |
| FY2021 | 2021-11-30 | (117.19M) | — |
Net Income vs competitors
How NRIX compares with its peers on the latest reported figures
- NRIX's LTM Aug 2026 net income of $294.88M is the 4th largest of the 8 companies compared; the peer median is $243.25M.
- Its year-over-year change of +220.5% is the 2nd highest of 8, against a peer median of +62.0%.
- Net income amounts to 42.0% of revenue for NRIX, versus a peer median of 285.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.77B | +117.8% | +65.7% | — | |
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
| LTM Jun 2026 | $299.6M | +8.8% | +26.2% | 285.4% | |
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Mar 2026 | $294.57M | +62.0% | +27.1% | 411.2% | |
| LTM Mar 2026 | $243.25M | -26.6% | +24.1% | 112.0% | |
| LTM Sep 2026 | $208M | +106.9% | -2.1% | — | |
| LTM Mar 2026 | $103.8M | +0.5% | -6.4% | 297.8% | |
| Peer median (excluding NRIX) | $243.25M | +62.0% | +25.2% | 285.4% | |
Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Nov 2021 | FY2022 Nov 2022 | FY2023 Nov 2023 | FY2024 Nov 2024 | FY2025 Nov 2025 |
|---|---|---|---|---|---|
| Net Income | (117.19M) | (180.36M) | (143.95M) | (193.57M) | (264.46M) |
| Depreciation & Amortization | 6.08M | 10.81M | 13.65M | 16.43M | 18.86M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.8M | 28.13M | 33.67M | 33.93M | 37.97M |
| Change in Working Capital | 9.11M | (19.02M) | 20.12M | (18.4M) | (31.6M) |
| Accounts Receivables | (6M) | 6M | 0 | 0 | 0 |
| Inventory | 6.77M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.59M | 85K | 1.61M | 5.21M | (630K) |
| Other Working Capital | 6.75M | (25.11M) | 18.51M | (23.61M) | (30.97M) |
| Other Non-Cash Items | 1.83M | 636K | (4.87M) | (10.97M) | (10.23M) |
| Operating Cash Flow | (84.37M) | (159.81M) | (81.37M) | (172.58M) | (249.47M) |
| Capital Expenditures | (5.66M) | (12.24M) | (8.4M) | (9.27M) | (14M) |
| Acquisitions (Net) | 102.59M | (39.44M) | 0 | 0 | 0 |
| Purchases of Investments | (348.5M) | (239.37M) | (246.33M) | (707.95M) | (455.69M) |
| Sales of Investments | 245.91M | 278.81M | 323.04M | 459.51M | 617.54M |
| Other Investing Activities | (102.59M) | 39.44M | 0 | 0 | 0 |
| Investing Cash Flow | (108.25M) | 27.2M | 68.3M | (257.71M) | 147.85M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 150.16M | 19.4M | 3.22M | 478.5M | 238.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.73M | 97.79M | 0 | 7.17M | 0 |
| Financing Cash Flow | 153.88M | 117.19M | 3.22M | 485.67M | 238.64M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (67K) |
| Net Change in Cash | (38.73M) | (15.42M) | (9.85M) | 55.37M | 137.03M |
| Free Cash Flow | (90.03M) | (172.05M) | (89.77M) | (181.86M) | (263.47M) |
Nurix Therapeutics, Inc.
NASDAQ:NRIX
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.